159 related articles for article (PubMed ID: 33015697)
1. Total synthesis of the actinoallolides and a designed photoaffinity probe for target identification.
Anketell MJ; Sharrock TM; Paterson I
Org Biomol Chem; 2020 Oct; 18(40):8109-8118. PubMed ID: 33015697
[TBL] [Abstract][Full Text] [Related]
2. A Unified Total Synthesis of the Actinoallolides, a Family of Potent Anti-Trypanosomal Macrolides.
Anketell MJ; Sharrock TM; Paterson I
Angew Chem Int Ed Engl; 2020 Jan; 59(4):1572-1576. PubMed ID: 31743574
[TBL] [Abstract][Full Text] [Related]
3. Actinoallolides A-E, new anti-trypanosomal macrolides, produced by an endophytic actinomycete, Actinoallomurus fulvus MK10-036.
Inahashi Y; Iwatsuki M; Ishiyama A; Matsumoto A; Hirose T; Oshita J; Sunazuka T; Panbangred W; Takahashi Y; Kaiser M; Otoguro K; Ōmura S
Org Lett; 2015 Feb; 17(4):864-7. PubMed ID: 25635351
[TBL] [Abstract][Full Text] [Related]
4. Identification and heterologous expression of the actinoallolide biosynthetic gene cluster.
Inahashi Y; Shiraishi T; Také A; Matsumoto A; Takahashi Y; Ōmura S; Kuzuyama T; Nakashima T
J Antibiot (Tokyo); 2018 Aug; 71(8):749-752. PubMed ID: 29679043
[TBL] [Abstract][Full Text] [Related]
5. 3-(Oxazolo[4,5-b]pyridin-2-yl)anilides as a novel class of potent inhibitors for the kinetoplastid Trypanosoma brucei, the causative agent for human African trypanosomiasis.
Ferrins L; Rahmani R; Sykes ML; Jones AJ; Avery VM; Teston E; Almohaywi B; Yin J; Smith J; Hyland C; White KL; Ryan E; Campbell M; Charman SA; Kaiser M; Baell JB
Eur J Med Chem; 2013 Aug; 66():450-65. PubMed ID: 23831695
[TBL] [Abstract][Full Text] [Related]
6. High-throughput screening platform for natural product-based drug discovery against 3 neglected tropical diseases: human African trypanosomiasis, leishmaniasis, and Chagas disease.
Annang F; Pérez-Moreno G; García-Hernández R; Cordon-Obras C; Martín J; Tormo JR; Rodríguez L; de Pedro N; Gómez-Pérez V; Valente M; Reyes F; Genilloud O; Vicente F; Castanys S; Ruiz-Pérez LM; Navarro M; Gamarro F; González-Pacanowska D
J Biomol Screen; 2015 Jan; 20(1):82-91. PubMed ID: 25332350
[TBL] [Abstract][Full Text] [Related]
7. Detection of trypanosomes in suspected sleeping sickness patients in Uganda using the polymerase chain reaction.
Kyambadde JW; Enyaru JC; Matovu E; Odiit M; Carasco JF
Bull World Health Organ; 2000; 78(1):119-24. PubMed ID: 10686746
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Protein-Protein Interactions: New Options for Developing Drugs against Neglected Tropical Diseases.
Berg T
Angew Chem Int Ed Engl; 2017 Sep; 56(40):12048-12050. PubMed ID: 28766862
[TBL] [Abstract][Full Text] [Related]
9. Priorities for the elimination of sleeping sickness.
Welburn SC; Maudlin I
Adv Parasitol; 2012; 79():299-337. PubMed ID: 22726645
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of a class of isatinoids identified from a high-throughput screen of human kinase inhibitors as anti-Sleeping Sickness agents.
Klug DM; Diaz-Gonzalez R; Pérez-Moreno G; Ceballos-Pérez G; García-Hernández R; Gomez-Pérez V; Ruiz-Pérez LM; Rojas-Barros DI; Gamarro F; González-Pacanowska D; Martínez-Martínez MS; Manzano P; Ferrins L; Caffrey CR; Navarro M; Pollastri MP
PLoS Negl Trop Dis; 2019 Feb; 13(2):e0007129. PubMed ID: 30735501
[TBL] [Abstract][Full Text] [Related]
11. Advances in Drug Discovery against Neglected Tropical Diseases: Human African and American Trypanosomiasis.
Peerzada MN; Gaur A; Azam A
Curr Med Chem; 2021; 28(36):7544-7582. PubMed ID: 33949927
[TBL] [Abstract][Full Text] [Related]
12. African trypanosomiasis with special reference to Egyptian Trypanosoma evansi: is it a neglected zoonosis?
El-Bahnasawy MM; Khater MKh; Morsy TA
J Egypt Soc Parasitol; 2014 Dec; 44(3):741-8. PubMed ID: 25643515
[TBL] [Abstract][Full Text] [Related]
13. Recent Updates on Development of Drug Molecules for Human African Trypanosomiasis.
Singh Grewal A; Pandita D; Bhardwaj S; Lather V
Curr Top Med Chem; 2016; 16(20):2245-65. PubMed ID: 27072715
[TBL] [Abstract][Full Text] [Related]
14. Non-natural acetogenin analogues as potent Trypanosoma brucei inhibitors.
Florence GJ; Fraser AL; Gould ER; King EF; Menzies SK; Morris JC; Tulloch LB; Smith TK
ChemMedChem; 2014 Nov; 9(11):2548-56. PubMed ID: 25145275
[TBL] [Abstract][Full Text] [Related]
15. Clinical and Neuropathogenetic Aspects of Human African Trypanosomiasis.
Kennedy PGE; Rodgers J
Front Immunol; 2019; 10():39. PubMed ID: 30740102
[TBL] [Abstract][Full Text] [Related]
16. Ornithine decarboxylase and S-adenosylmethionine decarboxylase in trypanosomatids.
Persson L
Biochem Soc Trans; 2007 Apr; 35(Pt 2):314-7. PubMed ID: 17371268
[TBL] [Abstract][Full Text] [Related]
17. Fexinidazole--a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness.
Torreele E; Bourdin Trunz B; Tweats D; Kaiser M; Brun R; Mazué G; Bray MA; Pécoul B
PLoS Negl Trop Dis; 2010 Dec; 4(12):e923. PubMed ID: 21200426
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in the diagnosis and treatment of African sleeping sickness.
Mbulamberi DB
Med Bull Uganda; 1994; 1(2):25-7. PubMed ID: 12288710
[TBL] [Abstract][Full Text] [Related]
19. Recent Theoretical Studies Concerning Important Tropical Infections.
Scotti MT; Monteiro AFM; de Oliveira Viana J; Bezerra Mendonça Junior FJ; Ishiki HM; Tchouboun EN; De Araújo RSA; Scotti L
Curr Med Chem; 2020; 27(5):795-834. PubMed ID: 31296154
[TBL] [Abstract][Full Text] [Related]
20. Drug discovery for the treatment of leishmaniasis, African sleeping sickness and Chagas disease.
Future Med Chem; 2013 Oct; 5(15):1709-18. PubMed ID: 24144408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
